Aytu BioScience Inc (AYTU)

Currency in USD
2.400
-0.040(-1.64%)
Closed·
After Hours
2.381-0.019(-0.81%)
·
AYTU Scorecard
Full Analysis
Net income is expected to grow this year
AYTU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.3202.420
52 wk Range
0.9502.850
Key Statistics
Prev. Close
2.44
Open
2.42
Day's Range
2.32-2.42
52 wk Range
0.95-2.85
Volume
86.85K
Average Volume (3m)
1.44M
1-Year Change
-4.76%
Book Value / Share
5.66
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AYTU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.667
Upside
+302.78%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Aytu BioScience Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Aytu BioScience Inc Company Profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Employees
102

Aytu BioScience Inc Earnings Call Summary for Q3/2025

  • Q3 FY2025 net revenue up 32% YoY to $18.5M; ADHD portfolio grew 25%, pediatric portfolio up 77%
  • Net income of $4M, reversing prior-year loss; adjusted EBITDA rose to $3.9M from $0.9M
  • Stock surged 52.6% in aftermarket trading to $2.06; company trading at attractive EV/EBITDA of 2.08x
  • CEO reports 3 consecutive quarters of positive net income, 8 quarters of positive adjusted EBITDA
  • Company exploring strategic acquisitions in CNS and pediatric areas; no specific financial guidance provided
Last Updated: 14/05/2025, 22:28
Read Full Transcript

Compare AYTU to Peers and Sector

Metrics to compare
AYTU
Peers
Sector
Relationship
P/E Ratio
−21.5x−1.3x−0.5x
PEG Ratio
−0.310.000.00
Price/Book
0.6x2.7x2.6x
Price / LTM Sales
0.3x2.1x3.3x
Upside (Analyst Target)
275.0%169.1%45.4%
Fair Value Upside
Unlock23.3%7.7%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.667
(+302.78% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
0.20 / --
Revenue / Forecast
18.45M / 17.59M
EPS Revisions
Last 90 days

AYTU Income Statement

People Also Watch

2.200
ONDS
+3.77%
25.91
CNC
-0.61%
0.3558
VXRT
-3.84%
4.7200
CLRB
-2.48%
1.640
IPA
-1.20%

FAQ

What Stock Exchange Does Aytu BioScience Trade On?

Aytu BioScience is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Aytu BioScience?

The stock symbol for Aytu BioScience is "AYTU."

What Is the Aytu BioScience Market Cap?

As of today, Aytu BioScience market cap is 21.54M.

What Is Aytu BioScience's Earnings Per Share (TTM)?

The Aytu BioScience EPS (TTM) is -0.17.

From a Technical Analysis Perspective, Is AYTU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Aytu BioScience Stock Split?

Aytu BioScience has split 6 times.

How Many Employees Does Aytu BioScience Have?

Aytu BioScience has 102 employees.

What is the current trading status of Aytu BioScience (AYTU)?

As of 03 Aug 2025, Aytu BioScience (AYTU) is trading at a price of 2.40, with a previous close of 2.44. The stock has fluctuated within a day range of 2.32 to 2.42, while its 52-week range spans from 0.95 to 2.85.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.